Table 1 Clinical trials of fecal microbiota transplantation in cancer immunotherapy
From: The gut microbiota in cancer immunity and immunotherapy
Cancer type | Study number | Phase | Immunotherapy | Enrollment | Country |
|---|---|---|---|---|---|
Head and neck squamous cell carcinoma, Cutaneous squamous cell carcinoma, Clear cell renal cell carcinoma, Melanoma, Non-small cell lung cancer | NCT05286294 | Phase 2 | ICB | 20 | Norway |
stage IV cancer | NCT05273255 | NA | ICB | 18 | Switzerland |
Solid tumor | NCT04264975 | NA | ICB | 60 | South Korea |
Liver cancer | NCT05690048 | Phase 2 | Atezolizumab | 48 | Germany |
Melanoma | NCT03353402 | Phase 1 | PD-1 blockade | 40 | Israel |
Lung cancer | NCT04924374 | NA | Pembrolizumab, Nivolizumab, Atezolizumab | 25 | Spain |
Renal cell carcinoma | NCT04163289 | Phase 1 | Ipilimumab, Nivolumab | 20 | Canada |
Metastatic lung cancer | NCT05502913 | Phase 2 | ICB | 80 | Israel |
Melanoma | NCT05251389 | Phase 1, 2 | ICB | 24 | Netherlands |
Gastrointestinal cancer | NCT04130763 | Phase 1 | PD-1 blockade | 10 | China |
Gastric cancer | NCT06405113 | Phase 2 | Sintilimab | 198 | China |
Non-small cell lung cancer | NCT06403111 | Phase 2 | Tislelizumab | 62 | China |
Metastatic colorectal cancer | NCT04729322 | Phase 2 | Pembrolizumab, Nivolumab | 15 | United States |
Non-small cell lung cancer | NCT05008861 | Phase 1 | Pembrolizumab, Nivolumab, Durvalumab, Sintilimab, Tislelizumab, Camrelizumab | 20 | China |
Advanced colorectal cancer | NCT06931808 | Phase 4 | Sintilimab | 20 | China |
Renal cell carcinoma | NCT04758507 | Phase 1, 2 | ICB | 50 | Italy |
Melanoma | NCT06623461 | Phase 2 | ICB | 128 | Canada |
Liver cancer | NCT05750030 | Phase 2 | Atezolizumab | 12 | Austria |
